Nuzenio

Darlifarnib Plus Cabozantinib

Darlifarnib Plus Cabozantinib news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 10 latest news signals 9 publisher sources 100/100 entity strength

Latest news

Kura Oncology, Inc. (KURA) stock price, news, quote and history - Yahoo Finance AustraliaYahoo Finance Australia · Sat, 08 Aug 2026 00:27:11 GMT Kura Oncology to Report Second Quarter Financial Results - GlobeNewswireGlobeNewswire · Wed, 05 Aug 2026 11:30:00 GMT Darlifarnib Plus Cabozantinib Yields ORRs Up to 50% in Cabozantinib-Naive ccRCC - OncLiveOncLive · Mon, 03 Aug 2026 12:07:09 GMT Adanma Ayanambakkam, MD, discusses phase 1 data on darlifarnib plus cabozantinib in RCC - Urology TimesUrology Times · Tue, 28 Jul 2026 07:00:00 GMT Charles Zhu Maintains Buy Rating on Kura Oncology, Reiterates $28 Price Target on Encouraging Darlifarnib Combination Data - TipRanksTipRanks · Mon, 27 Jul 2026 18:51:46 GMT KURA: Darlifarnib plus cabozantinib achieved up to 50% ORR and 13-month PFS in advanced RCC - TradingViewTradingView · Mon, 27 Jul 2026 15:23:28 GMT Darlifarnib Plus Cabozantinib Shows Durable Activity in Advanced RCC - Targeted OncologyTargeted Oncology · Mon, 27 Jul 2026 15:10:16 GMT KURA: Darlifarnib plus cabozantinib showed durable responses and manageable safety in advanced RCC - TradingViewTradingView · Mon, 27 Jul 2026 13:06:27 GMT

Timeline

Sat, 08 Aug 2026 00:27:11 GMTKura Oncology, Inc. (KURA) stock price, news, quote and history - Yahoo Finance Australia

Wed, 05 Aug 2026 11:30:00 GMTKura Oncology to Report Second Quarter Financial Results - GlobeNewswire

Mon, 03 Aug 2026 12:07:09 GMTDarlifarnib Plus Cabozantinib Yields ORRs Up to 50% in Cabozantinib-Naive ccRCC - OncLive

Tue, 28 Jul 2026 07:00:00 GMTAdanma Ayanambakkam, MD, discusses phase 1 data on darlifarnib plus cabozantinib in RCC - Urology Times

Mon, 27 Jul 2026 18:51:46 GMTCharles Zhu Maintains Buy Rating on Kura Oncology, Reiterates $28 Price Target on Encouraging Darlifarnib Combination Data - TipRanks

Mon, 27 Jul 2026 15:23:28 GMTKURA: Darlifarnib plus cabozantinib achieved up to 50% ORR and 13-month PFS in advanced RCC - TradingView

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

Kura Oncology5 live mentions KURA4 live mentions Cabozantinib4 live mentions Darlifarnib4 live mentions Yahoo Finance Australia3 live mentions RCC3 live mentions Inc2 live mentions Report Second Quarter2 live mentions Naive2 live mentions Reiterates2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Darlifarnib Plus Cabozantinib.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

9 distinct publisher/source names are currently connected to this entity page.